GO
| HSI1 | 24,642.51 | +132.42 | 177.48B |
| HSCEI1 | 8,216.84 | +51.06 | 51.28B |
| Back Zoom + Zoom - Block Traded | |
|
2026-09-25 12:08:24 Goldman Sachs issued a research report covering WUXI XDC (02268.HK), which has strong backlog order momentum and improving commercialization visibility, while remaining positive on its growth prospects for the coming years. Commercialization catalysts are also becoming increasingly visible, with process performance qualification (PPQ) projects reaching 21, and the number of biologics license application (BLA) submissions expected to increase. The broker gave WUXI XDC a Buy rating with a TP of HKD97.9. ~ AASTOCKS Financial News Website: www.aastocks.com | |